194 related articles for article (PubMed ID: 15482168)
21. Structural and biological characterization of pegylated recombinant interferon alpha-2b and its therapeutic implications.
Wang YS; Youngster S; Grace M; Bausch J; Bordens R; Wyss DF
Adv Drug Deliv Rev; 2002 Jun; 54(4):547-70. PubMed ID: 12052714
[TBL] [Abstract][Full Text] [Related]
22. [Side-effects of pegylated interferon plus ribavirin therapy with or without protease inhibitor direct acting antiviral agents during treatment of chronic hepatitis C virus infection].
Hunyady B; Kovács B; Battyáni Z
Orv Hetil; 2011 Dec; 152(50):1997-2009. PubMed ID: 22112373
[TBL] [Abstract][Full Text] [Related]
23. Relationship between the hepatitis C viral load and the serum interferon concentration during the first week of peginterferon-alpha-2b-ribavirin combination therapy.
François C; Descamps V; Brochot E; Bernard I; Canva V; Mathurin P; Castelain S; Duverlie G
J Med Virol; 2010 Oct; 82(10):1640-6. PubMed ID: 20827759
[TBL] [Abstract][Full Text] [Related]
24. Ribavirin and interferon alfa-2b in chronic hepatitis C: assessment of possible pharmacokinetic and pharmacodynamic interactions.
Khakoo S; Glue P; Grellier L; Wells B; Bell A; Dash C; Murray-Lyon I; Lypnyj D; Flannery B; Walters K; Dusheiko GM
Br J Clin Pharmacol; 1998 Dec; 46(6):563-70. PubMed ID: 9862245
[TBL] [Abstract][Full Text] [Related]
25. IDX184 in combination with pegylated interferon-α2a and ribavirin for 2 weeks in treatment-naive patients with chronic hepatitis C.
Lalezari J; Box T; O'Riordan W; Mehra P; Nguyen T; Poordad F; Dejesus E; Kwo P; Godofsky E; Lawrence S; Dubuc-Patrick G; Chen J; McCarville J; Pietropaolo K; Zhou XJ; Sullivan-Bólyai J; Mayers D
Antivir Ther; 2013; 18(6):755-64. PubMed ID: 23439365
[TBL] [Abstract][Full Text] [Related]
26. Pegylated IFNs for chronic hepatitis C: an update.
Grace MJ; Cutler DL; Bordens RW
Expert Opin Drug Deliv; 2005 Mar; 2(2):219-26. PubMed ID: 16296749
[TBL] [Abstract][Full Text] [Related]
27. Incidence of neutropenia and infections during combination treatment of chronic hepatitis C with pegylated interferon alfa-2a or alfa-2b plus ribavirin.
Antonini MG; Babudieri S; Maida I; Baiguera C; Zanini B; Fenu L; Dettori G; Manno D; Mura MS; Carosi G; Puoti M
Infection; 2008 Jun; 36(3):250-5. PubMed ID: 18458815
[TBL] [Abstract][Full Text] [Related]
28. Simeprevir plus peginterferon/ribavirin for HCV genotype 1-infected treatment-naïve patients in China and South Korea.
Wei L; Han T; Yang D; Heo J; Shang J; Cheng J; Chen X; Xie Q; Kim JH; Kalmeijer R; Ouwerkerk-Mahadevan S; Hoeben E; Lenz O; Verbinnen T; Sinha R; Li M; Scott J; Peeters M; Witek J;
J Gastroenterol Hepatol; 2016 May; 31(5):912-20. PubMed ID: 26777137
[TBL] [Abstract][Full Text] [Related]
29. Pegylated interferon-α2a with or without low-dose ribavirin for treatment-naive patients with hepatitis C virus genotype 1 receiving hemodialysis: a randomized trial.
Liu CH; Huang CF; Liu CJ; Dai CY; Liang CC; Huang JF; Hung PH; Tsai HB; Tsai MK; Chen SI; Lin JW; Yang SS; Su TH; Yang HC; Chen PJ; Chen DS; Chuang WL; Yu ML; Kao JH
Ann Intern Med; 2013 Dec; 159(11):729-38. PubMed ID: 24297189
[TBL] [Abstract][Full Text] [Related]
30. Lingual hyperpigmentation from pegylated interferon and ribavirin treatment of hepatitis C.
Farshidi D; Chiu MW
J Am Acad Dermatol; 2010 Jan; 62(1):164-165. PubMed ID: 20082904
[No Abstract] [Full Text] [Related]
31. Peginterferon alfa-2a plus ribavirin for the treatment of dual chronic infection with hepatitis B and C viruses.
Liu CJ; Chuang WL; Lee CM; Yu ML; Lu SN; Wu SS; Liao LY; Chen CL; Kuo HT; Chao YC; Tung SY; Yang SS; Kao JH; Liu CH; Su WW; Lin CL; Jeng YM; Chen PJ; Chen DS
Gastroenterology; 2009 Feb; 136(2):496-504.e3. PubMed ID: 19084016
[TBL] [Abstract][Full Text] [Related]
32. Severe interstitial pneumonitis secondary to pegylated interferon alpha-2b and ribavirin treatment of hepatitis C infection.
Fuhrmann V; Kramer L; Bauer E; Laferl H; Tucek G; Dekan G; Schenk P
Dig Dis Sci; 2004; 49(11-12):1966-70. PubMed ID: 15628735
[No Abstract] [Full Text] [Related]
33. Spotlight on peginterferon-alpha-2a (40KD) in chronic hepatitis C.
Perry CM; Jarvis B
BioDrugs; 2002; 16(3):213-7. PubMed ID: 12102649
[TBL] [Abstract][Full Text] [Related]
34. Peginterferon/ribavirin treatment achieves a higher compliance rate than interferon/ribavirin combination in patients chronically infected with HCV on methadone maintenance.
Dimitroulopoulos D; Petroulaki E; Manolakopoulos S; Anagnostou O; Tsaklakidou D; Xinopoulos D; Tsamakidis K; Tzourmakliotis D; Paraskevas E
Eur J Gastroenterol Hepatol; 2009 Dec; 21(12):1407-12. PubMed ID: 19916203
[TBL] [Abstract][Full Text] [Related]
35. Interferon alfa-2b in combination with ribavirin for the treatment of chronic hepatitis C in children: efficacy, safety, and pharmacokinetics.
González-Peralta RP; Kelly DA; Haber B; Molleston J; Murray KF; Jonas MM; Shelton M; Mieli-Vergani G; Lurie Y; Martin S; Lang T; Baczkowski A; Geffner M; Gupta S; Laughlin M;
Hepatology; 2005 Nov; 42(5):1010-8. PubMed ID: 16250032
[TBL] [Abstract][Full Text] [Related]
36. Comparison of quality of life, work productivity and medical resource utilization of peginterferon alpha 2a vs the combination of interferon alpha 2b plus ribavirin as initial treatment in patients with chronic hepatitis C.
Perrillo R; Rothstein KD; Rubin R; Alam I; Imperial J; Harb G; Hu S; Klaskala W
J Viral Hepat; 2004 Mar; 11(2):157-65. PubMed ID: 14996351
[TBL] [Abstract][Full Text] [Related]
37. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial.
Carrat F; Bani-Sadr F; Pol S; Rosenthal E; Lunel-Fabiani F; Benzekri A; Morand P; Goujard C; Pialoux G; Piroth L; Salmon-Céron D; Degott C; Cacoub P; Perronne C;
JAMA; 2004 Dec; 292(23):2839-48. PubMed ID: 15598915
[TBL] [Abstract][Full Text] [Related]
38. Peginterferon alpha-2a and ribavirin versus peginterferon alpha-2a monotherapy in early virological responders and peginterferon alpha-2a and ribavirin versus peginterferon alpha-2a, ribavirin and amantadine triple therapy in early virological nonresponders: the SMIEC II trial in naïve patients with chronic hepatitis C.
Angelico M; Koehler-Horst B; Piccolo P; Angelico F; Gentile S; Francioso S; Tarquini P; Vecchia RD; Ponti L; Pilleri G; Barlattani A; Grieco A; Soccorsi F; Guarascio P; Demelia L; Sorbello O; Rossi Z; Forlini G; Zaru S; Bandiera F;
Eur J Gastroenterol Hepatol; 2008 Jul; 20(7):680-7. PubMed ID: 18679072
[TBL] [Abstract][Full Text] [Related]
39. Peginterferon alpha/ribavirin combination therapy for the treatment of hepatitis C infection.
Zic I
Gastroenterol Nurs; 2005; 28(4):317-28. PubMed ID: 16189407
[TBL] [Abstract][Full Text] [Related]
40. Pegylated interferon (alone or with ribavirin) for chronic hepatitis C in haemodialysis population.
Espinosa M; Hernàndez J; Arenas MD; Carnicer F; Caramelo C; Fabrizi F
Kidney Blood Press Res; 2015; 40(3):258-65. PubMed ID: 25997572
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
